Serum levels of soluble TNFα receptor type 1 and the severity of systemic sclerosis

Acta Dermato-Venereologica

Volumn 79, Issue 3, 1999, Pages 207-210

  Majewski, Slawomir ^a,b   Wojas Pelc, Anna ^c   Malejczyk, Magdalena ^a,b   Szymanska, Elzbieta ^d   Jablonska, Stefania ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Institute of Venereology   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Cytokine receptors; Disease severity; Scleroderma

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; PROCOLLAGEN; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIGENS, CD; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LINEAR MODELS; MALE; MIDDLE AGED; PROCOLLAGEN; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SCLEROSIS; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 2942745707     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155599750010986     Document Type: Article

References (27)

1. 1. White B. Immune abnormalities in systemic sclerosis. Clin Dermatol 1994; 12: 349-359.
2. 2. Krieg T, Meurer M. Systemic scleroderma. J Am Acad Dermatol 1988; 18: 457-481.
3. 3. Degiannis D, Seibold J, Czarnecki M, Raskova J, Raska K. Soluble and cellular markers of immune activation in patients with systemic sclerosis. Clin Immunol Immunopathol 1990; 56: 259-270.
4. 4. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-α, and interferon-α levels in sera from patients with scleroderma. Arthritis Rheum 1992; 35: 67-72.
5. 5. Fagundus DM, LeRoy EC. Cytokines and systemic sclerosis. Clin Dermatol 1994; 12: 397-406.
6. 6. Majewski S, Hunzelmann N, Johnson JP, Jung JC, Mauch C, Ziegler-Heitbrock WI, et al. Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. J Invest Dermatol 1991; 97: 667-671.
7. 7. Gruschwitz M, von den Driesch P, Kellner I, Hornstein OP, Sterry W. Expression of adhesion proteins involved in cell-cell and cell-matrix interactions in the skin of patients with progressive systemic sclerosis. J Am Acad Dermatol 1992; 27: 169-177.
8. 8. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, Cho MM, Haines GK, Harlow LA, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Pathobiology 1993; 61: 239-246.
9. 9. Bruns M, Haustein UF, Hoffmann Ch, Herrman K. Serum levels of soluble IL-2 receptor, soluble ICAM-1, TNF-alpha, interleukin-4 and interleukin-6 in scleroderma. J Eur Acad Dermato Venereol 1997; 8: 222-228.
10. 10. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska KJr. Soluble interleukin-2 receptors in patients with systemic sclerosis. Arthritis Rheum 1990; 33: 375-380.
11. 11. Clements PJ, Peter JB, Agopian MS. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: Effect of chlorambucil. J Rheumatol 1990; 17: 908-910.
12. 12. Heilig B, Fiehn C, Brockhaus M, Brockhaus M, Gallati H, Pezzutto A, et al. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue diseases. J Clin Immunol 1993; 13: 321-328.
13. 13. Carson CW, Beall LD, Hunder GG, Johnson CM, Newman W. Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. J Rheumatol 1993; 20: 809-814.
14. 14. Gruschwitz MS, Hornstein OP, von den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38: 184-189.
15. 15. Subcommittee for scleroderma criteria of the ARA. Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
16. 16. Le Roy E, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis). Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
17. 17. Chorzelski TP, Jablonska S, Beutner EH, Blaszczyk M, Jarzabek-Chorzelska M, Kencka D, et al. Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. Br J Dermatol 1985; 113: 381-389.
18. 18. Jarzabek-Chorzelska M, Blaszczyk M, Jablonska S, Chorzelski TP, Kumar V, Beutner EH. Scl 70 antibody: a specific marker of systemic sclerosis. Br J Dermatol 1986; 115: 393-397.
19. 19. Jablonska S, Blaszczyk M, Chorzelski TP, Jarzabek-Chorzelska M, Kumar V, Beutner EH. Clinical relevance of immunologic findings in scleroderma. Clin Dermatol 1993; 10: 407-421.
20. 20. Jablonska S, Blaszczyk M, Jarzabek-Chorzelska M, Mejewski S, Rudnicka M. Scleroderma and dermatomyositis. In: Kanitakis J, Vassileva S, Woodley D., editors. Diagnostic immunohistochemistry of the skin. An illustrated text. London: Chapman and Hall Medical, 1998: 157-172.
21. 21. Krieg T, Langer G, Gerstheimer H, et al. Type III collagen aminopeptide levels in serum of patients with progressive systemic scleroderma. J Invest Dermatol 1986; 87: 788-791.
22. 22. Majewski S, Skiendzielewska A, Makiela B, Jablonska S, Blaszczyk M. Serum levels of type III collagen aminopropeptide levels in serum of patients with systemic scleroderma. Arch Dermatol Res 1987; 279: 484-486.
23. 23. Heickendorff L, Parvez A, Bjerring P, Halkier-Sörensen L, Zachariae H. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. Acta Derm Venereol (Stockh) 1991; 71: 185-188.
24. 24. Denton CP, Bickerstaff MCM, Shiwen X, Carullli MT, Haskard DO, Dubois RM, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995; 34: 1048-1054.
25. 25. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151-1153.
26. 26. Takeda K, Hatamochi A, Arakawa M, Ueki H. Effects of tumor necrosis factor-alpha on connective tissue metabolism in normal and scleroderma fibroblast cultures. Arch Dermatol Res 1993; 284: 440-444.
27. 27. Mauviel A, Heino J, Kahari VM, Hartmann DJ, Loyau G, Pujol JP, et al. Comparative effects of interleukin-1 and tumor necrosis factor-alpha on collagen production and corresponding procollagen mRNA levels of human dermal fibroblasts. J Invest Dermatol 1991; 96: 243-249.